Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related disorders. They generate revenue through the commercialization of their FDA-approved drugs, including Ingrezza for tardive dyskinesia and Orilissa for endometriosis pain, in collaboration with AbbVie. Founded in 1992, the company has a rich history of innovation, marked by its commitment to addressing unmet medical needs through cutting-edge research and development.

Recent Posts by Neurocrine Biosciences

1-20 of 158